Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | AHCY | P23526 | 6/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101383 | 1.00 | EGFR (0.65) | EGFRERBB2ADORA3AHCYADORA2B | |
| Putrescine SCHEMBL7124294 | 0.95 | EGFR (0.62) | EGFRERBB2ADORA3ADORA2BKMT2A | |
| SCHEMBL22326787 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL13173634 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL800381 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL18520788 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL16300875 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL21413837 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL22326785 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A | |
| SCHEMBL800346 | 0.90 | PRMT5 (0.64) | ADORA3AHCYADORA2BKMT2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577790-A | Application of metabolic marker in preparation of eye myasthenia gravis diagnostic reagent | 西安市第一医院 | 2026-02-27 | — | — | CN | claimed |
| CN-120166925-A | Synbiotic composition, metabolite and use thereof for preventing and treating obesity-related diseases | 徐丞志 | 2025-06-17 | — | — | CN | claimed |
| WO-2025085615-A1 | METHODS TO RAPIDLY DETECT METHYLTHIOADENOSINE AND RELATED METABOLITES DIRECTLY FROM PATIENT SAMPLES TO IDENTIFY 9P21 LOSS CANCERS AND TREATMENT STRATEGIES FOR PATIENTS | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | claimed |
| CN-119752753-A | Method for efficiently producing ergothioneine by metabolic engineering escherichia coli and application | 江南大学 | 2025-04-04 | — | — | CN | claimed |
| CN-116381072-B | Biomarker for identifying sporadic gout and frequent gout and application thereof | 苏州艾麦锶生命科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118011003-A | Biomarker composition for diagnosing gastric cancer and application thereof | 哈尔滨脉图精准技术有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-116381072-A | Biomarker for identifying sporadic gout and frequent gout and application thereof | 青岛大学附属医院 | 2023-07-04 | — | — | CN | claimed |
| CN-114515294-A | Application of 5' -methylthioadenosine in preparation of obesity inhibition drugs or health care products | 浙江中医药大学 | 2022-05-20 | — | — | CN | claimed |
| CN-121852489-A | Lactobacillus plantarum-derived mixture with antibacterial and anti-inflammatory activities and preparation method and application thereof | 广州医科大学附属第一医院（广州呼吸中心） | 2026-04-14 | — | — | CN | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121577790-A | Application of metabolic marker in preparation of eye myasthenia gravis diagnostic reagent | 西安市第一医院 | 2026-02-27 | — | — | CN | disclosed |
| US-20260014125-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| CN-114515294-A | Application of 5' -methylthioadenosine in preparation of obesity inhibition drugs or health care products | 浙江中医药大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-114515294-A | Application of 5' -methylthioadenosine in preparation of obesity inhibition drugs or health care products | 浙江中医药大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-114515294-A | Application of 5' -methylthioadenosine in preparation of obesity inhibition drugs or health care products | 浙江中医药大学 | 2022-05-20 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-114107268-A | Single-enzyme activity mutant prepared by ACS double-enzyme activity key site mutation of higher plants and application thereof | 南开大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114032229-A | Single enzyme mutant prepared by replacing ACS double-enzyme activity key structural domain of higher plant and application thereof | 南开大学 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014125-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | MAT2A, MNAT1, MAT1A | EGFR 4128/4885ERBB2 2751/4885ADORA3 1278/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | EGFR 1982/4885ERBB2 3492/4885ADORA3 534/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | EGFR 1299/4885ERBB2 2651/4885ADORA3 55/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | EGFR 383/4885ERBB2 693/4885ADORA3 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.